Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
absence, accessibility, actinic, acuminata, acuminate, add, arbitration, Atlantic, augmentation, balding, bankrupt, Belotero, bench, bid, bidding, carrier, Chapter, chronological, clotting, condyloma, contemplated, counter, Ct, default, Dist, diversification, driven, expedited, floor, genital, goal, Graceway, headcount, hereunder, imiquimod, immunocompetent, improperly, India, isde, jury, LAVIVTM, Leo, lip, maximize, meantime, Memorandum, memorialize, MetroGel, mouth, noncontributory, nose, novo, outbreak, overhead, palpable, panel, percentile, perianal, postpone, premium, principle, print, pump, rabbi, reassigned, remote, resignation, Resiquimod, respiratory, revaluation, Road, run, Sanofi, scalp, SERP, signatory, Solta, solvency, submucosal, summer, surrender, tier, twenty, unamortized, unnecessary, unplanned, Valeant, visible, Watson, withdrew, WL, women, wrapper, ZYCLARA
Removed:
accretion, Alternatively, andRESTYLANE, avian, Baddour, Baldini, BancBoston, begun, Bioglan, bring, carryforward, ceased, Clemente, comparably, contingency, Contingently, disposal, DYNACIN, EITF, Emmett, enterprise, ERP, Exorex, Flynn, Furman, Hanson, hazard, identifying, implementing, IMX, Inamed, indefinite, influenza, inquiry, introduced, irrevocable, Likewise, loan, Lotion, Masterpiece, merit, morbidity, mortality, MPC, mutation, nation, Norwest, Parallel, persist, pose, premarketing, Raymond, RELOXIN, remediate, remediated, retrospective, Robert, rosacea, sculpting, Seattle, Selz, SOLODYN®in, SUBQTM, sulfacetamide, sulfur, threatening, Tradename, treated, TRIAZ®branded, unenforceable, uninterrupted, vacating, Voting, Washington
Filing tables
Filing exhibits
- 10-K Annual report
- 12 Computation of Ratios of Earnings to Fixed Charges
- 21.1 Subsidiaries
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification of Chief Executive Officer Pursuant to Rule 13A-14(A) and Rule 15D
- 31.2 Certification of Chief Financial Officer Pursuant to Rule 13A-14(A) and Rule 15D
- 32.1 Certification of Chief Executive Officer Pursuant to 18 U.s.c. Section 1350
- 32.2 Certification of Chief Financial Officer Pursuant to 18 U.s.c. Section 1350
Related press release
Medicis Pharmaceutical similar filings
Filing view
External links
Exhibit 12
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(in thousands)
Years Ended December 31, | ||||||||||||||||||||
2007 | 2008 | 2009 | 2010 | 2011 | ||||||||||||||||
EARNINGS: | ||||||||||||||||||||
Income from continuing operations before income tax expense | $ | 118,980 | $ | 83,464 | $ | 165,895 | $ | 249,024 | $ | 183,158 | ||||||||||
Add: Fixed charges | 11,839 | 9,431 | 6,510 | 6,276 | 6,586 | |||||||||||||||
|
| |||||||||||||||||||
Earnings as defined | $ | 130,819 | $ | 92,895 | $ | 172,405 | $ | 255,300 | $ | 189,744 | ||||||||||
|
| |||||||||||||||||||
FIXED CHARGES: | ||||||||||||||||||||
Interest expense | $ | 8,495 | $ | 6,008 | $ | 4,228 | $ | 4,236 | $ | 4,668 | ||||||||||
Amortization of deferred financing fees | 1,523 | 666 | — | — | — | |||||||||||||||
|
| |||||||||||||||||||
Interest expense as reported | 10,018 | 6,674 | 4,228 | 4,236 | 4,668 | |||||||||||||||
Portion of rent expense as interest | 1,821 | 2,757 | 2,282 | 2,040 | 1,918 | |||||||||||||||
|
| |||||||||||||||||||
Fixed charges as defined | $ | 11,839 | $ | 9,431 | $ | 6,510 | $ | 6,276 | $ | 6,586 | ||||||||||
|
| |||||||||||||||||||
Ratio of earnings to fixed charges | 11.1x | 9.9x | 26.5x | 40.7x | 28.8x |
For purposes of computing the ratios of earnings to fixed charges, earnings represent pretax income from continuing operations plus fixed charges. Fixed charges represent interest expense and the portion of rents representative of interest related to continuing operations.